Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
February 07 2024 - 8:00AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2024
Commission file number: 001-40231
Universe Pharmaceuticals INC
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development
Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Receipt of Nasdaq Letter
On January 23, 2024, Universe
Pharmaceuticals INC (the “Company”) applied to transfer its ordinary shares, originally listed on the Nasdaq Global Market,
to the Nasdaq Capital Market (the “Capital Market”), as allowed under the Nasdaq Listing Rules. On January 30, 2024, Nasdaq
Listing Qualifications notified the Company that its transfer from the Nasdaq Global Market to the Capital Market was approved, and the
Company’s securities were transferred to the Capital Market at the opening of business on February 1, 2024.
SIGNATURES
Pursuant to the requirements of
the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
Universe Pharmaceuticals INC |
|
|
Date: February 7, 2024 |
By: |
/s/ Gang Lai |
|
|
Gang Lai |
|
|
Chief Executive Officer |
2
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Sep 2024 to Oct 2024
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Oct 2023 to Oct 2024